Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

GeneDx Holdings Corp. Class A (WGS)

NASDAQ: WGS · Services-Health Services · Stamford, CT

Our rating: Positive

First call: Positive, moderate conviction, at $104.95, moderate conviction, September 17, 2026.

Breaks if: The Positive call fails if full-year revenue growth drops below 20% in the next reported annual period (from 40% today), signaling that the volume acceleration has peaked; or if free cash flow turns negative for two consecutive reported quarters, indicating the cash-generation thesis was premature. A 35% drawdown from the current price over the next twelve months, absent a broad market dislocation, would likely be pricing in the same deterioration before the financials confirm it.

Key figures

Market value$1.4B
Revenue, last 12 months$461M
Net income, last 12 months−$111M
Free cash flow, last 12 months−$102M
Price to earningsn/a
Free cash flow yield−7.5%
Dividend yield0.0%
Operating margin−21.6%
Return on equity−41.4%
Beta to the S&P 5001.68
Volatility, annualized96.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$123M5.4%$-0.41n/a
June 30, 2026$114M11.4%$-0.60−$39M
March 31, 2026$102M17.4%$-2.16−$39M
December 31, 2025$121M26.5%$-0.61−$7M
September 30, 2025$117M51.9%$-0.27$10M
June 30, 2025$103M45.6%$0.36$8M
March 31, 2025$87M39.6%$-0.23$4M
December 31, 2024$96M66.6%$0.23−$6M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 39 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.